Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg , M.D., M.
S., to Chief Medical Officer Ended second quarter 2024 with cash, cash equivalents, and investments of $95.9 million ; Cash runway into H1 2026 SAN DIEGO , Aug.
8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS ), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2024 , and provided a corporate update. "We were very pleased with the data we shared in the second quarter from our ongoing Phase 1b MAD study.
Data from cohort three showed continued improvement on both polycystin and height adjusted total kidney volume (htTKV) after just three months of treatment, consistent with what was observed in cohort 2 but with greater mechanistic activity in polycystin changes and more patients showing reductions in kidney volume," said Jay Hagan , CEO of Regulus. "This growing data set leaves us excited about the potential of RGLS8429 as a treatment for those living with ADPKD, a disease with high unmet need and limited treatment options. We remain on track to meet with FDA near the end of this year.
" RGLS8429 for ADPKD: In May 2024 , the Company announced that it has advanced.